Highlights NovoCure Limited

Equities

NVCR

JE00BYSS4X48

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-17 pm EDT			5-day change	1st Jan Change
21.99 ^USD	-0.81%		+33.52%	+47.29%

May. 02	NovoCure Shares Steady After Reporting Narrower Q1 Loss, Higher Revenue	MT
May. 02	BioPharma Credit Enters $400 Million Loan Agreement with Novocure Luxembourg	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

NovoCure Shares Steady After Reporting Narrower Q1 Loss, Higher Revenue	May. 02	MT
BioPharma Credit Enters $400 Million Loan Agreement with Novocure Luxembourg	May. 02	MT
BioPharma Credit agrees USD400 million loan for oncology firm Novacure	May. 02	AN
Earnings Flash (NVCR) NOVOCURE Reports Q1 Revenue $138.5M, vs. Street Est of $131.5M	May. 02	MT
NovoCure Limited Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 02	CI
NovoCure Limited Announces Results of the Metis Phase 3 Clinical Trial in Brain Metastases from Non-Small Cell Lung Cancer	Apr. 24	CI
NovoCure Says New Data Show TTFields' Potential Therapeutic Effects in Pancreatic Cancer	Apr. 05	MT
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Wednesday Ahead of Fed Board Governor Waller's Speech	Mar. 27	MT
Novocure Q4 Net Loss Widens, Revenue Rises	Feb. 22	MT
Earnings Flash (NVCR) NOVOCURE Reports Q4 Revenue $133.8M	Feb. 22	MT
NovoCure Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 22	CI
NovoCure Says US FDA Accepts Its Premarket Approval Application for Tumor Treating Fields in Lung Cancer; Shares Rise	Jan. 18	MT
Novocure Shares Rise 17% After FDA Accepts Pre-Market Application	Jan. 18	DJ
Novocure Announces FDA Acceptance of the PMA Application for TTFields Therapy in Non-Small Cell Lung Cancer	Jan. 18	CI
NovoCure Limited Announces Last Patient Enrolled in Phase 3 Trident Trial in Newly Diagnosed Glioblastoma	Jan. 09	CI
NovoCure Reports Higher Q4 Preliminary Revenue; Shares Rise	Jan. 08	MT
Novocure Preliminary Full Year 2023 Net Revenues Of $509 Mln And Q4 Net Revenues Of $134 Mln	Jan. 08	RE
Novocure Announces Portfolio Prioritization and Strategic Restructuring Plan Focused on Near-Term Growth Drivers and an Accelerated Path to Profitability	Nov. 28	CI
Earnings Flash (NVCR) NOVOCURE Reports Q3 Revenue $127.3M, vs. Street Est of $128.8M	23-10-26	MT
NovoCure Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23-10-26	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights NovoCure Limited

Equities

NVCR

JE00BYSS4X48

Highlights

Filters